CN104649981A - Symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor - Google Patents
Symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor Download PDFInfo
- Publication number
- CN104649981A CN104649981A CN201510075378.2A CN201510075378A CN104649981A CN 104649981 A CN104649981 A CN 104649981A CN 201510075378 A CN201510075378 A CN 201510075378A CN 104649981 A CN104649981 A CN 104649981A
- Authority
- CN
- China
- Prior art keywords
- sglt2
- compound
- symmetrical
- carboxylic acid
- acid benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(C)OC(N[C@@](*)C(O)=O)=O Chemical compound CC(C)(C)OC(N[C@@](*)C(O)=O)=O 0.000 description 6
- PQFBWUSGCOKLBK-UHFFFAOYSA-N Cc1cc(C)nc(NCCCN)n1 Chemical compound Cc1cc(C)nc(NCCCN)n1 PQFBWUSGCOKLBK-UHFFFAOYSA-N 0.000 description 1
- LMTOWNMJYBIWTI-UHFFFAOYSA-N Cc1nc(SC)nc(C)c1 Chemical compound Cc1nc(SC)nc(C)c1 LMTOWNMJYBIWTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Abstract
The invention relates to the field of type-2 diabetes related drugs and particularly relates to a symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with a pyrimidine structure, a preparation method of the symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor and application of the symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor to preparation of drugs for treating type-2 diabetes. The formula (I) is as shown in the specification.
Description
Technical field
The present invention relates to the pharmaceutical field of the treatment of diabetes B.Specifically, the present invention relates to the medicative a kind of symmetrical ring cyclohexane carboxylic-acid benzyl amide SGLT2/SGLT1 containing pyrimidine structure of diabetes B two target spot inhibitor, its preparation method and the purposes in pharmacy.
Background technology
The metabolic disease of diabetes to be a kind of with hyperglycemia be feature.Hyperglycemia be then due to defect of insulin secretion or its biological action impaired, or both have concurrently and cause.Long-standing hyperglycemia during diabetes, causes various tissue, particularly eye, kidney, heart, blood vessel, neural chronic lesion, dysfunction.There is no the method for radical cure diabetes at present, but suitably can be controlled diabetes progression by multiple treatment means.Mainly comprise several aspect: the education of diabetic subject, self-monitoring of blood glucose, dietetic treatment, exercise therapy and pharmacological agent.Oral hypoglycaemic medicine by a variety of, as sulfonylurea, biguanides, thiazolidinediones, glycosidase inhibitor class, etc., but these medicines generally have various different side effect, as hepatotoxicity, hypoglycemia, abdominal distension, heart disease risk, etc.Therefore the medicine of brand-new action target spot is active demand clinically.
Sodium-glucose co-transporters body (sodium-glucose linked transporter, SGLT) be a kind of glucose transporter, there are two kinds of hypotypes and SGLT1 and SGLT2, both all have distribution in renal proximal tubules, 10% and 90% are respectively to the contribution of glucose reabsorption in kidney, in addition SGLT1 is also distributed in enteron aisle, is responsible for the absorption of glucose in enteron aisle together with GLUT.Suppress SGLT2 that the glucose in uriniferous tubules can be made heavily not absorb smoothly enter blood and discharge with urine, thus reduce blood sugar concentration, the SGLT2 inhibitor of listing at present has multiple, as dapagliflozin, canagliflozin and empagliflozin etc.
Inhibitor of these listings are all optionally SGLT2 inhibitor, very weak to SGLT1 restraining effect.At the initial stage of SGLT2 inhibitor research and development, the selectivity of SGLT2/SGLT1 was once considered to very important index, because suppress SGLT1 may cause intestines and stomach side reaction in theory.But research in recent years shows, this theoretic worry there is no need, and confirm by the clinical trial of LX4211 (Zambrowicz B, et al.Effects of LX4211, a dual sodium-dependent glucosecotransporters 1and 2inhibitor, on postprandial glucose, insulin, glucagon-likepeptide 1, and peptide tyrosine in a dose-timing study in healthy subjects, Clin Ther., 2013,35 (8), 1162-1173.e8).Because SGLT2/SGLT1 inhibitor can suppress SGLT1 further on the basis suppressing SGLT2, and this suppression can increase the discharge of glucose in urine in kidney and reduce the absorption of glucose in enteron aisle, therefore this kind of inhibitor is considered to a kind of selection of control blood sugar completely newly.
The invention discloses the two target spot inhibitor of a kind of symmetrical ring cyclohexane carboxylic-acid benzyl amide SGLT2/SGLT1 containing pyrimidine structure, these compounds can be used for the medicine preparing treatment diabetes B.
Summary of the invention
An object of the present invention is to provide and a kind of there is the two target spot inhibit activities of good SGLT2/SGLT1, there is the non-glucoside compound of one of formula I.Another object of the present invention is to provide the method that preparation has the compound of formula I.Another object of the present invention is to provide compound containing formula I as effective constituent, and the medicinal compositions of one or more pharmaceutically acceptable carrier, vehicle or thinners, and the application in treatment diabetes B.Now in conjunction with object of the present invention, content of the present invention is specifically described.
Formula I has following structural formula:
Formula I of the present invention is synthesized by following route:
Compound II per, reacting with 1,3-propylene diamine (III), obtains compound IV; Being there is lower condensation by the amino acid V that tertbutyloxycarbonyl (Boc) is protected at DCC (N, N-dicyclohexyl carbodiimide) with amino in compound IV, obtains compound VI; Compound VI is sloughed protecting group through acid treatment and is obtained compound VI I; Compound VI I and compound VI II condensation under DCC exists obtains Compound I; Wherein the definition of R as previously mentioned.
Formula I of the present invention has the double inhibition effect of SGLT2/SGLT1, can be used as the medicine of effective constituent for the preparation of diabetes B.The activity of formula I of the present invention is verified by receptor binding assays.Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking formula I can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I-1
A. the synthesis of compound IV-1
1.86g (10mmol) Compound II per-1 is dissolved in 50mL THF, and stirred at ambient temperature, adds 10mL1,3-propylene diamine (III), and then stir lower backflow 3 hours, TLC detection reaction completes.After having reacted, be poured into after reaction mixture is slightly cold in 200mL frozen water, stir, use the CH of 100mL × 5
2cl
2extraction, merges extraction phase, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=181 ([M+H]
+).
B. the synthesis of compound VI-1
1.26g (7mmol) compound IV-1 and 1.86g (7mmol) V-1 are dissolved in the THF of 30mL drying, stirred at ambient temperature, add 2.06g (10mmol) DCC and 1.00g DMAP (DMAP), then room temperature for overnight.After having reacted, add 50mL methyl tertiary butyl ether in reaction mixture, then stir 1 hour, suction filtration, filtrate pours in 300mL frozen water, stirs, and uses the CH of 100mL × 3
2cl
2extraction, merges extraction phase, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid, ESI-MS, m/z=428 ([M+H]
+).
C. the synthesis of compound VI I-1
1.71g (4mmol) compound VI-1 is dissolved in 10mL methyl alcohol, stirred at ambient temperature, slowly drips trifluoroacetic acid 2mL, then at room temperature stirs and spends the night.TLC detection reaction completes.After having reacted, reaction mixture is poured in 100mL frozen water, stirs, and uses saturated sodium carbonate solution to regulate pH=9, with the CH of 50mL × 5
2cl
2extraction, merges extraction phase, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI I-1, white solid, ESI-MS, m/z=328 ([M+H]
+).
D. the synthesis of Compound I-1
6.54g (2mmol) compound VI I and 1.72g (1mmol) compound VI II is dissolved in the THF of 20mL drying, stirred at ambient temperature, add 0.41g (2mmol) DCC and 0.50g DMAP (DMAP), then room temperature for overnight.After having reacted, add 30mL methyl tertiary butyl ether in reaction mixture, then stir 1 hour, suction filtration, filtrate pours in 100mL frozen water, stirs, and uses the CH of 50mL × 3
2cl
2extraction, merges extraction phase, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid, ESI-MS, m/z=792 ([M+H]
+).
embodiment 2 Compound ira vitro is to the suppression of people SGLT2 and people SGLT1
Prepared by people SGLT2 expression vector
To full length cDNA clone (purchased from GenScript company) (having put Hind III and Not I site at the cDNA two ends) subclone of people SGLT2 be expressed between the Hind III and Not I site of pEAK15 expression vector (Theracos company of the U.S.).The method of the clone's digestion with restriction enzyme containing target gene is determined.
Prepared by people SGLT2 stably transfected cell line
Utilize restriction enzyme Nsi I to digest the plasmid containing people SGLT2, make it linearizing, with agarose gel electrophoresis, purifying is carried out to linear DNA.With transfection reagent Lipofectamine2000 (Invitrogen company), the DNA after purifying is proceeded to HEK293 cell (Theracos company of the U.S.).By the cell after transfection containing 10% foetal calf serum DMEM substratum in 37 DEG C, 5%CO
2cultivate under condition after 24 hours, in identical growth medium, add purine mycin (Invitrogen company) continue cultivation 2 weeks, the cell after screening with puromycin-resistant is inoculated in (one, every hole cell) in 96 new orifice plates, cultivate in the substratum containing purinase element, until cell grows to converging state.There is the methyl-α-D-[U-of cell clone by reflection SGLT2 activity of puromycin-resistant
14c] pyranoside picked-up test screening (experimental technique has detailed description hereinafter) further.Select the cell clone with highest signal to noise ratio for follow-up methyl-α-D-[U-
14c] pyranoside picked-up test.
Prepared by people SGLT1 express cell
PDream2.1 expression vector containing total length people SGLT1cDNA is purchased from GenScript company.Plasmid increases in bacillus coli DH 5 alpha, and this strain culturing is in Luria-Bertani (LB) substratum containing penbritin.With QIAGEN Plasmid Midi test kit (QIAGEN company) extracting plasmid.With Lipofectamine 2000 transfection reagent, according to the method for operational manual, people SGLT1 expression vector plasmid is proceeded to COS-7 cell (purchased from American Type Tissue Collection).Transfectional cell in containing the DMEM of 10%DMSO in-80 DEG C of preservations.
Methyl-α-D-[U-
14c] pyranoside picked-up test
Before test, the DMEM of cell containing 10%FBS expressing SGLT1 and SGLT2 is respectively inoculated in 96 holes ScintiPlate liquid sudden strain of a muscle plate (PerkinElmer company), and (every hole adds 100 μ L nutrient solutions, containing 1 × 105 cell), and in 37 DEG C, cultivate 48 hours under 5%CO2 condition.Cell 150 μ L contain sodium damping fluid (137mM NaCl, 5.4mM KCl, 2.8mM CaCl
2, 1.2mM MgCl
210mM Tutofusin tris/N-2-hydroxyethyl piperazine-N '-ethane sulfonic acid [Tris/Hepes], pH7.2) or without sodium damping fluid (137mM N-methyl-glucamine, 5.4mM KCl, 2.8mM CaCl2,1.2mM MgCl2,10mMTris/Hepes, pH7.2) wash twice.Testing compound is dissolved in containing 25% human plasma and 40 μ Ci/mL methyl-α-D-[U-
14c] pyranoside (Amersham Biosciences/GE Healthcare) containing sodium or without in sodium damping fluid, be prepared into the testing compound solution of a series of suitable concn.The 96 every holes of orifice plate add 50 μ L testing compound solutions, shaking culture 2 hours (SGLT1 analysis) or 1.5 hours (SGLT2 analysis).Cell 150 μ L cleaning buffer solution (137mM N-METHYL-ALPHA-L-GLUCOSAMINEs, 10mM Tris/Hepes, pH7.2) wash twice, with TopCount liquid scintillation counter (Perkin Elmer company), quantitative analysis is carried out to the picked-up of methyl-α-D-[U-14C] pyranoside.Sodium dependency pyranoside intake is the difference (mean value of three wells) deducting the intake obtained without the process of sodium damping fluid by the intake obtained containing the process of sodium damping fluid.
Shown in the following list of result.
The IC that part of compounds of the present invention suppresses people SGLT2 and people SGLT1
50value
| Compound | IC 50(hSGLT2,nM) | IC 50(hSGLT1,nM) |
| dapagliflozin | 1.2 | 1248 |
| Compound I-1 | 6.3 | 5.7 |
Above-mentioned IC
50measurement result show, compound of the present invention is the two target spot inhibitor of strong SGLT2/SGLT1, can be used for preparing the medicine for the treatment of diabetes B.
Claims (3)
1. there is the compound of general formula I,
2. synthesize the method for formula I described in claim 1:
Compound II per, reacting with 1,3-propylene diamine (III), obtains compound IV; Being there is lower condensation by the amino acid V that tertbutyloxycarbonyl (Boc) is protected at DCC (N, N-dicyclohexyl carbodiimide) with amino in compound IV, obtains compound VI; Compound VI is sloughed protecting group through acid treatment and is obtained compound VI I; Compound VI I and compound VI II condensation under DCC exists obtains Compound I.
3. the application of formula I described in claim 1 in preparation treatment diabetes B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510075378.2A CN104649981A (en) | 2015-02-11 | 2015-02-11 | Symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510075378.2A CN104649981A (en) | 2015-02-11 | 2015-02-11 | Symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104649981A true CN104649981A (en) | 2015-05-27 |
Family
ID=53241683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510075378.2A Pending CN104649981A (en) | 2015-02-11 | 2015-02-11 | Symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104649981A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027627A1 (en) * | 1993-05-24 | 1994-12-08 | Smithkline Beecham Corporation | Hemoregulatory peptides |
| EP0819118B1 (en) * | 1995-03-24 | 2002-09-18 | Polychip Pharmaceuticals Pty. Ltd. | Potassium ion channel blockers |
| WO2005095357A2 (en) * | 2004-03-30 | 2005-10-13 | Taisho Pharmaceutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| CN102066335A (en) * | 2008-04-22 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | Substituted pyrimidin-5-carboxamides 281 |
| WO2012070114A1 (en) * | 2010-11-24 | 2012-05-31 | 塩野義製薬株式会社 | Sulfamide derivative having npy y5 receptor antagonism |
-
2015
- 2015-02-11 CN CN201510075378.2A patent/CN104649981A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027627A1 (en) * | 1993-05-24 | 1994-12-08 | Smithkline Beecham Corporation | Hemoregulatory peptides |
| EP0819118B1 (en) * | 1995-03-24 | 2002-09-18 | Polychip Pharmaceuticals Pty. Ltd. | Potassium ion channel blockers |
| WO2005095357A2 (en) * | 2004-03-30 | 2005-10-13 | Taisho Pharmaceutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| CN102066335A (en) * | 2008-04-22 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | Substituted pyrimidin-5-carboxamides 281 |
| WO2012070114A1 (en) * | 2010-11-24 | 2012-05-31 | 塩野義製薬株式会社 | Sulfamide derivative having npy y5 receptor antagonism |
Non-Patent Citations (3)
| Title |
|---|
| BRIAN ZAMBROWICZ ET AL: "Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor，Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes", 《CLINICAL THERAPEUTICS》 * |
| BRIAN ZAMBROWICZ ET AL: "Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose,Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects", 《CLINICAL THERAPEUTICS》 * |
| 曾要富 等: "SGLT2 抑制剂Canagliflozin——Ⅱ型糖尿病治疗的新药", 《中国现代应用药学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104649981A (en) | Symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid benzyl amide SGLT2/SGLT1 double-target inhibitor | |
| CN104592131A (en) | Pyrimidine structure-contained symmetrical cyclohexane carboxylic acid benzyl amide compound and application thereof | |
| CN104649980A (en) | Symmetrical cyclohexane carboxylic acid amide SGLT2/SGLT1 double-target inhibitor with pyrimidine structure as well as preparation method and application of symmetrical cyclohexane carboxylic acid amide SGLT2/SGLT1 double-target inhibitor | |
| CN104628656A (en) | Symmetric cyclohexanecarboxamide type double-target-point inhibitor containing pyrimidine structure and application | |
| CN104628671B (en) | Containing oil of mirbane thiazole carboxylic acid amides compounds and the purposes of benzene carbon amidine structure | |
| CN104725347A (en) | Alkoxy-substituted compounds containing methoxyphenyl thiophene amide structures and application | |
| CN104610187B (en) | One class is containing alkoxyphenyl radical thiazole carboxylic acid amides class two target spot inhibitor, the Preparation Method And The Use of amidine structure | |
| CN104592152A (en) | Amidine structure containing nitrobenzene thiazolecarboxylic acid amide dual-target inhibitor, as well as preparation method and application thereof | |
| CN104672207B (en) | The two target spot inhibitor of a kind of nitrothiophene acid amides toluene class and purposes thereof | |
| CN104610188A (en) | Nitrile benzene thiazolecarboxamide type compound containing phenyl amidine structure as well as preparation method and application thereof | |
| CN104592148A (en) | Cyclopropyl amidine structure containing nitrobenzene thiazolecarboxylic acid amide compound and application thereof | |
| CN104557766A (en) | Nitrobenzene thiazolecarboxylic acid amide compounds containing tert-butylformamidine structure and application thereof | |
| CN104672165B (en) | One class is containing alkoxyphenyl radical thiazole carboxylic acid amides's class two target spot inhibitor, the Preparation Method And The Use of cyclopropyl amidine structure | |
| CN104672166A (en) | Cyanophenyl thiazolecarboxylic acid amide double-target inhibitor containing amidine structure as well as preparation method and application of inhibitor | |
| CN104628673A (en) | Nitrile benzene thiazolecarboxamide type compound containing tert-butylamidine structure and application thereof | |
| CN104592150A (en) | Cyclopropyl amidine structure containing cyanobenzene thiazolecarboxylic acid amide compound and application thereof | |
| CN104592153A (en) | SGLT2/SGLT1 dual-target inhibitor, as well as preparation method and application thereof | |
| CN104610190B (en) | One class contains halogenophenyl thiazole carboxylic acid amides's compounds and the purposes of cyclopropyl amidine structure | |
| CN104610189A (en) | SGLT2/SGLT1 double-target-point inhibitor containing cyclopropyl amidine structure and application of SGLT2/SGLT1 double-target-point inhibitor | |
| CN104592151A (en) | Tert-butyl amidine structure containing SGLT2/SGLT1 dual-target inhibitor and application thereof | |
| CN104672164A (en) | SGLT2/SGLT1 double-target inhibitor containing benzene amidine structure as well as preparation method and application of inhibitor | |
| CN104628672A (en) | Alkoxyphenylthiazole carboxylic acid amide compounds containing phenylamidine structures and application | |
| CN104610223A (en) | Thiophene amide toluene type SGLT2/SGLT1 double-target point inhibitor and application thereof | |
| CN104592149A (en) | Tert-butyl amidine structure containing alkoxyphenyl thiazolecarboxylic acid amide dual-target inhibitor, as well as preparation method and application thereof | |
| CN104693170A (en) | Alkoxy thiophene amide double-target-point inhibitor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150527 |